-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $39

Benzinga·11/10/2026 17:36:10
Listen to the news
Mizuho analyst Graig Suvannavejh maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $38 to $39.